Bachem has entered a strategic collaboration with Eli Lilly and Co. to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.   Bachem will provide the engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology. Bachem will also provide R&D and production personnel at its facilities in Bubendorf, Switzerland, for the development and manufacture of GMP-grade material for ...